Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Intra-Cellular Therapies, Inc. ITCI
$64.40
+$0.03 (0.05%)
На 18:00, 12 мая 2023
+4.04%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
6193915992.00000000
-
week52high
66.56
-
week52low
42.01
-
Revenue
249132000
-
P/E TTM
-24
-
Beta
1.14048400
-
EPS
-2.77000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Buy | 22 авг 2022 г. |
| Mizuho | Buy | Buy | 11 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 10 авг 2022 г. |
| Needham | Buy | Buy | 10 авг 2022 г. |
| Mizuho | Buy | 07 июл 2022 г. | |
| Cantor Fitzgerald | Overweight | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| VAN NOSTRAND ROBERT L | A | 9250 | 97 | 30 дек 2022 г. |
| RIGGS RORY B | A | 78047 | 321 | 30 дек 2022 г. |
| MARCUS JOEL S | D | 29233 | 5000 | 19 дек 2022 г. |
| Mates Sharon | D | 1100309 | 33083 | 13 дек 2022 г. |
| Halstead Michael | D | 15164 | 50000 | 01 дек 2022 г. |
| Halstead Michael | D | 0 | 22796 | 01 дек 2022 г. |
| Halstead Michael | D | 22796 | 27204 | 01 дек 2022 г. |
| Halstead Michael | A | 50000 | 50000 | 01 дек 2022 г. |
| MARCUS JOEL S | D | 34233 | 5000 | 07 ноя 2022 г. |
| MARCUS JOEL S | D | 39233 | 5000 | 07 ноя 2022 г. |
Новостная лента
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
GlobeNewsWire
02 мая 2023 г. в 08:00
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at two upcoming investor conferences:
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
GlobeNewsWire
26 апр 2023 г. в 08:00
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 4, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2023.
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
Zacks Investment Research
21 апр 2023 г. в 12:56
Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
31 мар 2023 г. в 13:04
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
Zacks Investment Research
29 мар 2023 г. в 13:46
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.